NCT04647656 Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome
| NCT ID | NCT04647656 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assaf-Harofeh Medical Center |
| Condition | Covid19 |
| Study Type | INTERVENTIONAL |
| Enrollment | 91 participants |
| Start Date | 2023-06-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 91 participants in total. It began in 2023-06-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome
Eligibility Criteria
Inclusion Criteria: 1. Age above 18 years 2. Reported post COVID-19 cognitive deterioration that effect quality of life and persist at least 3 months after confirmed infection. 3. Subject willing and able to read, understand and sign an informed consent Exclusion Criteria: 1. Inability to attend scheduled clinic visits and/or comply with the study protocol 2. History of traumatic brain injury (TBI) or any other non COVID brain pathology 3. Active malignancy 4. Substance use at baseline 5. Severe or unstable physical disorders or major cognitive deficits at baseline 6. HBOT for any reason prior to study enrolment 7. Chest pathology incompatible with pressure changes (including moderate to severe asthma) 8. Ear or Sinus pathology incompatible with pressure changes 9. An inability to perform an awake brain MRI 10. Active smoking
Contact & Investigator
Shai a Efrati, MD
PRINCIPAL INVESTIGATOR
Asaf-Harofhe MC
Frequently Asked Questions
Who can join the NCT04647656 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Covid19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04647656 currently recruiting?
Yes, NCT04647656 is actively recruiting participants. Contact the research team at shani.zilberman@mail.huji.ac.il for enrollment information.
Where is the NCT04647656 trial being conducted?
This trial is being conducted at Ẕerifin, Israel.
Who is sponsoring the NCT04647656 clinical trial?
NCT04647656 is sponsored by Assaf-Harofeh Medical Center. The principal investigator is Shai a Efrati, MD at Asaf-Harofhe MC. The trial plans to enroll 91 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.